1,249
Views
30
CrossRef citations to date
0
Altmetric
Clinical Studies

Superior Outcome of Nafamostat Mesilate as an Anticoagulant in Patients Undergoing Maintenance Hemodialysis with Intracerebral Hemorrhage

, , , , , & show all
Pages 668-675 | Received 08 Apr 2009, Accepted 17 May 2009, Published online: 09 Oct 2009

Figures & data

Figure 1. Methods for volume of hematoma and interval change of CT: (a) admission, (b) two weeks later. On the CT slice with the largest area of ICH, the largest diameter (A) of the hematoma was measured by use of the centimeter scale on the CT film. The diameter of the hemorrhage perpendicular to the largest diameter represented the second diameter (B). The height of the hematoma was calculated by multiplying the number of slices involved by the slice thickness, providing the third diameter. The three diameters were multiplied and then divided by 2 (AxBxC/2) to obtain the volume of ICH (this formula was validated by Kwak et al.).

Figure 1.  Methods for volume of hematoma and interval change of CT: (a) admission, (b) two weeks later. On the CT slice with the largest area of ICH, the largest diameter (A) of the hematoma was measured by use of the centimeter scale on the CT film. The diameter of the hemorrhage perpendicular to the largest diameter represented the second diameter (B). The height of the hematoma was calculated by multiplying the number of slices involved by the slice thickness, providing the third diameter. The three diameters were multiplied and then divided by 2 (AxBxC/2) to obtain the volume of ICH (this formula was validated by Kwak et al.).

Table 1 Epidemiology and characteristics of total patients

Table 2 Comparison of risk factors between nafamostat and heparin groups

Table 3 Comparison of risk factors between resolving and expansion groups

Table 4 Comparison of risk factors among four groups about change of hematoma size

Table 5 Chi-square test about CT changes and anticoagulants

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.